In the drug development and especially in advanced biologics, cell and gene therapies, the word innovation is everywhere. New vectors, new editing tools, new platforms, when it comes to biosafety and quality control, innovation meets specific challenges. It’s about translating evolving guidelines into robust, GMP-compliant assays and deploying them in a way that fits manufacturing constraints, especially for time-critical products and vulnerable patients.
This is exactly where Clean Cells operates between regulators’ expectations, developers’ practical needs, and patient safety.
